Search General Info
Search Education
Search Partnering Companies
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health.
Our lead product candidate, oteseconazole (VT-1161), is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects 138 million women worldwide. Commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity.
With no FDA-approved treatments for RVVC in the U.S., there are limited treatment options available for women who experience three or more yeast infections a year. Mycovia has enrolled three Phase 3 clinical studies being conducted to evaluate oteseconazole for the treatment of RVVC and is on path to be the first FDA-approved treatment for this debilitating disease.
Our lead product candidate, oteseconazole (VT-1161), is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects 138 million women worldwide. Commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity.
With no FDA-approved treatments for RVVC in the U.S., there are limited treatment options available for women who experience three or more yeast infections a year. Mycovia has enrolled three Phase 3 clinical studies being conducted to evaluate oteseconazole for the treatment of RVVC and is on path to be the first FDA-approved treatment for this debilitating disease.
![](/sites/default/files/hubb_images/2996/attachments/%2520-%2520f1_Mycovia_20Pharmaceuticals_94ae1caf.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Reproductive/Sexual Health
Lead Product in Development:
Oteseconazole (VT-1161)
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved